Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Amortization (2019 - 2024)

Silence Therapeutics' Amortization history spans 6 years, with the latest figure at $204.7 million for Q3 2024.

  • On a quarterly basis, Amortization rose 84.43% to $204.7 million in Q3 2024 year-over-year; TTM through Sep 2024 was $204.7 million, a 84.43% increase, with the full-year FY2023 number at $100.6 million, down 15.96% from a year prior.
  • Amortization hit $204.7 million in Q3 2024 for Silence Therapeutics, down from $222.6 million in the prior quarter.
  • Over the last five years, Amortization for SLN hit a ceiling of $230.5 million in Q1 2024 and a floor of $92.5 million in Q2 2022.
  • Historically, Amortization has averaged $130.6 million across 5 years, with a median of $113.0 million in 2020.
  • The widest YoY moves for Amortization: up 321.87% in 2020, down 51.78% in 2020.
  • Tracing SLN's Amortization over 5 years: stood at $100.9 million in 2020, then rose by 15.36% to $116.4 million in 2021, then decreased by 2.55% to $113.4 million in 2022, then decreased by 11.33% to $100.6 million in 2023, then surged by 103.52% to $204.7 million in 2024.
  • Business Quant data shows Amortization for SLN at $204.7 million in Q3 2024, $222.6 million in Q2 2024, and $230.5 million in Q1 2024.